<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486326</url>
  </required_header>
  <id_info>
    <org_study_id>2020P-000464</org_study_id>
    <nct_id>NCT04486326</nct_id>
  </id_info>
  <brief_title>Crofelemer for Functional Diarrhea</brief_title>
  <official_title>Crofelemer for Functional Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the clinical response of patients with&#xD;
      diarrhea to crofelemer relative to placebo and evaluate the overall safety and tolerability&#xD;
      of crofelemer in the treatment of diarrhea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bristol Stool Form Scale</measure>
    <time_frame>week 8</time_frame>
    <description>measures stool consistency by type from 1-7</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>crofelemer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crofelemer</intervention_name>
    <description>Crofelemer</description>
    <arm_group_label>crofelemer</arm_group_label>
    <other_name>mytesi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is a man or woman aged 18 to 65 years, inclusive, at Screening.&#xD;
&#xD;
          2. Patient has functional diarrhea defined by the Rome IV criteria as loose (mushy) or&#xD;
             watery stools ≥25% and hard or lumpy stools &lt;25% of bowel movements&#xD;
&#xD;
          3. Patient has had a colonoscopy performed:&#xD;
&#xD;
               1. Within 10 years prior to Prescreening if patient is at least 50 years of age&#xD;
                  (alternatively, a flexible sigmoidoscopy, double contrast barium enema, or CT&#xD;
                  colonography within the past 5 years is acceptable [see recommendations of the&#xD;
                  American Cancer Society])&#xD;
&#xD;
               2. Since the onset (if applicable) of any of the following alarm features for&#xD;
                  patients of any age (see Spiller and Thompson, 2010 - i.e. Patient has documented&#xD;
                  weight loss within the past 6 months; Patient has nocturnal symptoms; Patient has&#xD;
                  a familial history of colon cancer; or patient has blood mixed with their stool&#xD;
                  (excluding any blood from hemorrhoids).&#xD;
&#xD;
          4. Patient has an average daily stool consistency score (BSS) of ≥5.5 on days without the&#xD;
             use of an anti-diarrheal and at least 3 days with a BSS score ≥5 on a 1 to 7 scale&#xD;
             over the week prior to randomization.&#xD;
&#xD;
          5. Patient has completed the daily diary on at least 6 of the 7 days during the week&#xD;
             prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          6. Patient has not used loperamide rescue medication more than 4 days during the&#xD;
             screening period.&#xD;
&#xD;
          7. Patient is not planning to change his/her usual diet and lifestyle during the course&#xD;
             of the study.&#xD;
&#xD;
          8. Patient is willing to be compliant with study procedures including completing the&#xD;
             daily diary during the screening period and throughout the study.&#xD;
&#xD;
          9. Patient must sign an informed consent document before the initiation of any&#xD;
             study-related procedures indicating that he or she understands the purpose of and&#xD;
             procedures required for the study and is willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a history of inflammatory or immune-mediated GI disorders including&#xD;
             inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis, microscopic&#xD;
             colitis) and celiac disease.&#xD;
&#xD;
          2. Patient has a predominant symptom of abdominal pain.&#xD;
&#xD;
          3. Patient has a history of diverticulitis within 3 months prior to screening. Patients&#xD;
             with a history of diverticulosis are candidates for the study.&#xD;
&#xD;
          4. Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI&#xD;
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic&#xD;
             colitis, or impaired intestinal circulation (eg, aortoiliac disease).&#xD;
&#xD;
          5. Patient has any of the following surgical history:&#xD;
&#xD;
               1. Any abdominal surgery within the 3 months prior to screening; or&#xD;
&#xD;
               2. Patient has a history of major gastric, hepatic, pancreatic, or intestinal&#xD;
                  surgery (appendectomy, cholecystectomy, hemorrhoidectomy, or polypectomy greater&#xD;
                  than 3 months are allowed). For the purposes of this study, laparoscopic&#xD;
                  surgeries without complication are considered minor and non-exclusionary,&#xD;
                  provided the condition for which the surgery was performed was not exclusionary.&#xD;
&#xD;
          6. Patient has an unstable renal, hepatic, metabolic, or hematologic condition.&#xD;
&#xD;
          7. Patient has a history of human immunodeficiency virus infection.&#xD;
&#xD;
          8. Patient has a history of DSM-IV-TR-defined substance dependency, excluding nicotine&#xD;
             and caffeine, within 2 years prior to Prescreening.&#xD;
&#xD;
          9. Patient has a history of alcohol abuse as defined by DSM-IV-TR, binge drinking as&#xD;
             defined by the National Institutes on Alcohol Abuse and Alcoholism, or any medical&#xD;
             treatment for alcohol-related co-morbidities, within 5 years prior to Prescreening.&#xD;
             Recovered alcoholics who have not consumed alcohol over the 5 years prior to&#xD;
             Prescreening are candidates for the study.&#xD;
&#xD;
         10. Patient has current (within 14 days of randomization) or expected use of any narcotic&#xD;
             or opioid containing agents, tramadol&#xD;
&#xD;
         11. Patient is unable to swallow solid, oral dosage forms whole with the aid of liquid&#xD;
             (patients may not chew, divide, dissolve, or crush the study drug).&#xD;
&#xD;
         12. Patient has received an investigational drug or used an investigational medical device&#xD;
             within 30 days prior to randomization.&#xD;
&#xD;
         13. Patient has a known pregnancy or is breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Lembo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Cheng, MS, MPH</last_name>
    <phone>617.667.0682</phone>
    <email>vcheng2@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Cheng, MS, MPH</last_name>
      <phone>617-667-0682</phone>
      <email>vcheng2@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Lembo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

